LOGIN  |  REGISTER
Cue Biopharma

Tactile Medical to Present at Two Upcoming Conferences in March

March 02, 2023 | Last Trade: US$14.30 0.03 0.21

MINNEAPOLIS, March 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:

The 33rd Oppenheimer Annual Healthcare Conference, which is being held virtually from March 13th-15th.

  • Management will participate in a virtual fireside chat on Monday, March 13th at 12:40 p.m. Eastern Time.

The Sidoti Small-Cap Conference, which is being held virtually from March 22nd-23rd.

  • Management will present on Wednesday, March 22nd at 2:30 p.m. Eastern Time.

Live audio webcasts of the presentations will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. Archives of the webcasts will be available for replay following each conference.

About Tactile Medical

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB